000			02313 a2200685 4500
005			20250517003950.0
264		0	_c20150223
008			201502s 0 0 eng d
022			_a1474-5488
024	7		_a10.1016/S1470-2045(14)70455-3 _2doi
040			_aNLM _beng _cNLM
100	1		_aFowler, Nathan H
245	0	0	_aSafety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. _h[electronic resource]
260			_bThe Lancet. Oncology _cNov 2014
300			_a1311-8 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntibodies, Monoclonal, Murine-Derived _xadministration & dosage
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols
650	0	4	_aDisease-Free Survival
650	0	4	_aDrug Administration Schedule
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aLenalidomide
650	0	4	_aLymphoma, Follicular _xdrug therapy
650	0	4	_aLymphoma, Non-Hodgkin _xdrug therapy
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aNeoplasm Recurrence, Local _xdrug therapy
650	0	4	_aNeoplasm Staging
650	0	4	_aRituximab
650	0	4	_aThalidomide _xadministration & dosage
650	0	4	_aTreatment Outcome
700	1		_aDavis, R Eric
700	1		_aRawal, Seema
700	1		_aNastoupil, Loretta
700	1		_aHagemeister, Fredrick B
700	1		_aMcLaughlin, Peter
700	1		_aKwak, Larry W
700	1		_aRomaguera, Jorge E
700	1		_aFanale, Michelle A
700	1		_aFayad, Luis E
700	1		_aWestin, Jason R
700	1		_aShah, Jatin
700	1		_aOrlowski, Robert Z
700	1		_aWang, Michael
700	1		_aTurturro, Francesco
700	1		_aOki, Yasuhiro
700	1		_aClaret, Linda C
700	1		_aFeng, Lei
700	1		_aBaladandayuthapani, Veerabhadran
700	1		_aMuzzafar, Tariq
700	1		_aTsai, Kenneth Y
700	1		_aSamaniego, Felipe
700	1		_aNeelapu, Sattva S
773	0		_tThe Lancet. Oncology _gvol. 15 _gno. 12 _gp. 1311-8
856	4	0	_uhttps://doi.org/10.1016/S1470-2045(14)70455-3 _zAvailable from publisher's website
999			_c24394655 _d24394655